Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Brochure for doctors
Learn how to switch your patients from capsules to tablets and ensure a smooth transition
Introducing ZEJULA tablets
ZEJULA is now available in a tablet formulation, which is bioequivalent to, and interchangeable with, ZEJULA capsules.*†1
At GSK, we are committed to supporting your transition from capsules to tablets: explore the brochures below for you, your clinic and your patients.
Switching your patients to the ZEJULA tablet formulation
Get in touch with GSK for more information
All imagery shown depicts hypothetical patients only.
*In a pharmacokinetic study with 108 patients with solid tumours, under fasting conditions, one 300 mg tablet was bioequivalent to three 100 mg capsules, based on plasma concentration of niraparib.1 For more information on these data, please refer to the Summary of Product Characteristics.
†ZEJULA capsules can be taken without regard to meals. It is advised to take ZEJULA tablets without food (at least 1 hour before or 2 hours after a meal) or with a light meal.1
Zejula Safety Information1:
Contraindications:
Hypersensitivity to the active substances or to any of the excipients.
Special warnings and precautions:
Haematologic adverse reactions (thrombocytopenia, anaemia, neutropenia) have been reported. Discontinue if a patient develops severe persistent haematologic toxicity including pancytopenia that does not resolve within 28 days following interruption.
Use with caution in patients on anticoagulants and medicinal products known to reduce the thrombocyte count hypertension, hepatic impairment.
Pregnancy/contraception:
Should not be used during pregnancy or in women of childbearing potential.
Adverse Events:
Very common: Urinary Tract Infections, thrombocytopenia, anaemia, neutropenia, leukopenia, decreased appetite, insomnia.
Please refer to the local prescribing information for a more detailed safety information.
Abbreviations
FIGO, International Federation of Gynecology and Obstetrics.
References
- ZEJULA (niraparib) Prescribing information.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية المديرية العامة للصيدلة و الرقابة الدوائية وزارة الصحة, سلطنة عمان 0096822357687 / 0096822357686 :هاتف 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد الالكتروني www.moh.gov.om :الموقع الالكتروني |
Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor. All rights reserved.
PM-RCH-NRP-SRCH-240001 | April 2024
